Search

Issue
Title
Authors
Vol 27, No 2 (2025)
Novel therapies for the metastatic HER2-positive breast cancer with metastases in the central nervous system: a clinical case
Radyukova I.M., Rats N.M.
PDF
(Rus)
Vol 15, No 2 (2013)
Breast cancer: from guidelines to personalized oncology
PierFranco C., Valentina G.
Vol 23, No 4 (2021)
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III
Morozov D.A., Kolyadina I.V., Poddubnaya I.V., Ganshina I.P., Khokhlova S.V., Kоmetova V.V., Rodionov V.V.
PDF
(Rus)
Vol 16, No 3 (2014)
Personalized approach to HER2-positive advanced breast cancertherapy
Stenina M.B.
Vol 20, No 2 (2018)
Optimal duration of adjuvant trastuzumab therapy in patients with HER2-possitive early breast cancer: whether the problem is resolved?
Zhukova L.G., Ganshina I.P., Khatkova E.I., Tikhomirova T.E., Kondratyeva O.E.
PDF
(Rus)
Vol 16, No 2 (2014)
High efficiency of lapatinib in combination with capecitabine in patient with metastatic HER2-positive synchronous breast cancer (case study)
Seryakov A.P., Ovchinnikova L.K., Zabelin M.V., Yakubov T.Z., Sidorov D.B., Ovchinnikov M.V.
Vol 19, No 1 (2017)
Pharmacoeconomic aspects of biosimilars
Tryakin A.A., Rudakova A.V., Fogt S.N., Vaganov A.S., Tolkacheva D.G.
PDF
(Rus)
Vol 18, No 2 (2016)
Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study
Ignatova E.O., Burdaeva O.N., Kopp M.V., Kotiv B.N., Udovitsa D.P., Stroiakovskii D.L., Alekseev S.M., Sheveleva L.P., Khorinko A.V., Shapovalova I.S., Moiseenko V.M., Ivanov R.A.
PDF
(Rus)
Vol 15, No 1 (2013)
Current approach to adjuvant therapy for breast cancer (a review)
Conte P., Guarneri V.
Vol 17, No 4 (2015)
Neoadjuvant systemic therapy of HER2-positive breast cancer
Frolova M.A.
Vol 27, No 1 (2025)
Evolution of anti-HER2 therapy in advanced HER2+ breast cancer or “why is trastuzumab still a key player?”. A review
Grechukhina K.S., Sukhova M.V., Kolyago E.M., Filonenko D.A., Zhukova L.G.
PDF
(Rus)
Vol 17, No 2 (2015)
Brain metastases in her2-positive breast cancer: new opportunities for systemic therapy
Artamonova E.V., Manziuk L.V.
Vol 25, No 3 (2023)
Real-world experience with trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and HER2-positive gastric cancer: A retrospective study
Evdokimov V.I., Bloshchinenko A.A., Abolmasov A.E., Vilensky A.A., Laskov M.S.
PDF
(Rus)
Vol 16, No 4 (2014)
The effect of combinated treatment of a metastatic HER2-positive stomach cancer
Khvastunov R.A., Nenarokomov A.Y., Tolstopiatov S.E., Babina K.G.
Vol 25, No 1 (2023)
Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review
Kolyadina I.V.
PDF
(Rus)
Vol 16, No 3 (2014)
HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment
Besova N.S.
1 - 16 of 16 Items

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default only articles containing all terms in the query are returned (i.e., AND is implied)
  • Combine multiple words with OR to find articles containing either term; e.g., education OR research
  • Use parentheses to create more complex queries; e.g., archive ((journal OR conference) NOT theses)
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing"
  • Exclude a word by prefixing it with - or NOT; e.g. online -politics or online NOT politics
  • Use * in a term as a wildcard to match any sequence of characters; e.g., soci* morality would match documents containing "sociological" or "societal"